Clinical Trial Update: Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis [Phase 1]

View source ↗

Summary

This clinical trial update reports on evaluating the safety and tolerability of baricitinib in patients with Hyper-IgE syndrome due to STAT3 mutations with lupu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis
• Hyper-ige Syndrome
• Systemic Lupus Erythematosus

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome | Phase 1 | Status: RECRUITING